Astrazeneca (AZN) Other Accumulated Expenses (2009 - 2026)

Astrazeneca has reported Other Accumulated Expenses for 18 years, with the latest figure at -$2.0 billion in Q2 2026.

• On a quarterly basis, Other Accumulated Expenses fell 23.19% year-over-year to -$2.0 billion in Q2 2026; TTM through Jun 2026 was -$2.0 billion, a 23.19% decrease from a year earlier, with the FY2025 full-year figure at -$2.4 billion, down 34.41% from the prior year.
• Other Accumulated Expenses was -$2.0 billion for Q2 2026 at Astrazeneca, up from -$2.2 billion in the prior quarter.
• The five-year high for Other Accumulated Expenses was -$1.6 billion in Q2 2025, with the low at -$4.9 billion in Q3 2022.
• Average Other Accumulated Expenses over 5 years is -$2.7 billion, with a median of -$2.3 billion recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: Other Accumulated Expenses jumped 54.04% in 2023, then slumped 34.41% in 2025.
• Over 5 years, Other Accumulated Expenses stood at -$4.3 billion in 2022, then soared by 37.7% to -$2.7 billion in 2023, then surged by 33.46% to -$1.8 billion in 2024, then plunged by 34.41% to -$2.4 billion in 2025, then gained by 17.15% to -$2.0 billion in 2026.
• The last three Other Accumulated Expenses figures came in at -$2.0 billion (Q2 2026), -$2.2 billion (Q1 2026), and -$2.4 billion (Q4 2025), per Business Quant data.